Ion; 2011.doi:10.11861475-2875-12-450 Cite this article as: Quashie et
Ion; 2011.doi:10.11861475-2875-12-450 Cite this article as: Quashie et al.: A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs. Malaria Journal 2013 12:450.Submit your next manuscript to BioMed Central and take complete advantage of:Practical on the web submission Thorough peer assessment No space constraints or colour figure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Study which can be freely offered for redistributionSubmit your manuscript at biomedcentralsubmit
HIPPOKRATIA 2013, 17, two:187-CASE REPORTBleomycin cardiotoxicity during chemotherapy for an ovarian germ cell tumorDidagelos M, Boutis A, Diamantopoulos N, Sotiriadou M, Fotiou C1st Department of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, Thessaloniki, GreeceAbstract Introduction: Platinum-based chemotherapeutic KDM2 medchemexpress regimens, which includes BEP (bleomycin, etoposide, cisplatin) represent the common of care, CYP2 Storage & Stability initial line therapy in non-epithelial ovarian tumours. Cardiovascular toxicity can be a uncommon adverse impact of bleomycin. Case Report: A 41-year-old lady with ovarian granulosa tumor, treated with initial line BEP chemotherapy knowledgeable chest discomfort quickly progressing to serious precordial discomfort during bleomycin infusion. The infusion was stopped and electrocardiographic changes indicative of myocardial ischemia were revealed. Anti-anginal and anti-thrombotic remedy was introduced. Cardiac enzymes were not elevated and echocardiographic findings showed no wall motion abnormalities. Twenty four hours right after the episode the elctrocardiographic modifications insisted and chemotherapy was decided to become continued, excluding bleomycin, with no symptom recurrence. Discussion: Cardiovascular complications pose a rare but prospective fatal adverse effect of BEP chemotherapy and should be very carefully addressed, particularly in individuals with more cardiovascular danger aspects. Physicians coping with bleomycin-based therapies may possibly discover this information useful for a far more extensive evaluation of chest discomfort syndromes in these sufferers. Hippokratia 2013, 17, two: 1787-188 Keyword phrases: BEP chemotherapy, ovarian cancer, cardiotoxicity, myocardial ischemia, chest painCorresponding Author: Anastasios Boutis, 1st Department of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, 54007, Thessaloniki, Greece, tel.: 302310898711, 306937040299, fax:302310845514, e-mail: alboutisotenet.grIntroduction BEP (bleomycin, etoposide, cisplatin) chemotherapeutic regimen represents the typical of care initial line therapy in non-epithelial ovarian tumours1. Cardiovascular toxicity can be a rare adverse impact of bleomycin and could be expressed clinically as hypotension, pericarditis, acute substernal chest discomfort, coronary artery illness, myocardial ischemia, myocardial infarction, cerebral vascular accident and Raynaud’s phenomenon2. Case report A 41-year-old lady with sophisticated recurrent ovarian cancer (adult granulosa cell tumor, initial stage pT2b pN1 M0, FIGO IIIC, 4 years before) was treated with initial line platinum-based chemotherapy. Pre-treatment cardiovascular danger components incorporated arterial hypertension (well controlled with angiotensin II receptor blockers) and obesity (BMI: 40.3 Kgm2). Baseline cardiologic evaluation with ECG and echocardiogram just prior to initiation of chemotherapy was unremarkable. Through the initial cycle of therapy and in the course of the bleomycin infusion, ch.